论文部分内容阅读
目的探讨老年晚期非小细胞肺癌患者的临床特点和应用吉非替尼治疗的临床疗效。方法选取2009年1月—2013年10月接受治疗的200例老年晚期非小细胞肺癌患者为研究对象,采用随机数字表法将患者平均分成二组,观察组与对照组,每组各100例。对照组患者给予多西紫衫醇治疗,75mg/m2,静滴;观察组实施吉非替尼治疗,250mg/d,口服。总结老年晚期非小细胞肺癌患者的临床特点并比较二组患者的临床疗效。结果 200例老年晚期非小细胞肺癌患者中男女比例近3:1,61%的患者有吸烟史,腺癌和鳞癌患者达174例(87%)。观察组患者与对照组相比较,治疗有效率为(36%vs12%),控制率为(74%vs 43%),中位生存时间为(7.3vs 3.9)个月,均明显高于对照组,二组比较差异有统计学意义(P<0.05)。结论应用吉非替尼治疗老年晚期非小细胞肺癌可以显著改善患者的临床症状,延长患者的生存期,临床疗效显著,且不良反应轻微,安全性好,是临床治疗老年晚期非小细胞肺癌的有效途径。
Objective To investigate the clinical features of elderly patients with advanced non-small cell lung cancer and the clinical efficacy of gefitinib. Methods A total of 200 elderly patients with advanced non-small cell lung cancer treated from January 2009 to October 2013 were selected as subjects. The patients were divided equally into two groups by random number table method. The observation group and the control group were treated with 100 cases in each group . Patients in the control group were treated with docetaxel, 75mg / m2, intravenously; the observation group was treated with gefitinib, 250mg / d orally. To summarize the clinical features of patients with advanced non-small cell lung cancer and to compare the clinical efficacy of the two groups. Results Among 200 elderly patients with advanced non-small cell lung cancer, there was a history of smoking in nearly 3: 1,61% of the patients, while adenocarcinoma and squamous cell carcinoma in 174 patients (87%). The effective rate of treatment was (36% vs 12%) in control group (74% vs 43%) and the median survival time was (7.3 vs 3.9) months in observation group compared with that in control group , The difference between the two groups was statistically significant (P <0.05). Conclusion The application of gefitinib in elderly patients with advanced non-small cell lung cancer can significantly improve the clinical symptoms, prolong the survival of patients with significant clinical effects, and minor adverse reactions, safety, clinical treatment of elderly patients with advanced non-small cell lung cancer Effective Ways.